Roche CEO Grapples with Swiss Franc Surge: Resilient Commitment to U.S. Investment Amidst Challenges
Roche has reported a decline in sales for the first quarter of the year, attributing this downturn to the strong Swiss franc and increased generic competition for its older medications. The Swiss pharmaceutical giant’s sales reached 14.7 billion Swiss francs ($18.7 billion), reflecting a 5% drop year-on-year, though it marked a 6% increase when adjusted for constant currency. The appreciation of the Swiss franc against major currencies, particularly the U.S. dollar, significantly impacted the financial results, the company noted.
The strength of the Swiss franc has been notable, having risen 12% against the U.S. dollar last year and continuing to climb by an additional 1% in early 2023. CEO Thomas Schinecker defended the company’s performance, highlighting how one can interpret these figures. He pointed out that while results in Swiss francs showed a decline, sales reported in U.S. dollars actually rose by 9%. “We spend most of our money in the U.S. and have most of our debt there; we’ve also recently acquired another company in the U.S.,” Schinecker stated during an interview on Squawk Box Europe. He emphasized Roche’s commitment to investment in the U.S., viewing it as a non-issue.
Following the earnings announcement, Roche’s shares gained 2% in midmorning trading in Zürich, contributing to a robust 12-month gain of 18%. The company, through its U.S. subsidiary Genentech, has recently engaged in agreements to streamline drug prices for American consumers in exchange for a grace period against proposed tariffs, contingent upon further investments in U.S. manufacturing. Last April, Roche committed to investing $50 billion in the U.S. over the next five years, aiming to create 1,000 direct jobs and an additional 11,000 to bolster its manufacturing capabilities.
The pharmaceutical sector is under pressure as many companies, including Roche, face the upcoming expiration of exclusivity for older drugs, allowing for generic competition to enter the market. To counter this risk, Roche is pursuing both in-house development and strategic acquisitions to enhance future sales. Recent announcements included promising trial results for an experimental multiple sclerosis pill, which significantly reduced relapse rates, although safety concerns lingered.
Looking forward, Roche plans to submit the new medication for FDA approval by mid-2023, with analysts from Barclays indicating a potential for upside despite the concerns. Additionally, Roche is focusing on entering the lucrative weight-loss pharmaceutical market, aiming to secure a spot among the top three players alongside industry leaders Novo Nordisk and Eli Lilly. Schinecker commented in a recent interview that Roche seeks to capture a double-digit market share, noting the market’s early stage and significant potential for growth in addressing weight management.
In Roche’s primary market, the U.S., sales have seen a 5% growth, attributed to successful products like the asthma medication Xolair, the hemophilia treatment Hemlibra, and the blood cancer drug Polivy. The company’s pharmaceutical and diagnostics divisions have reported growth rates of 7% and 3%, respectively. Roche has maintained its full-year sales guidance, targeting mid-single-digit growth for 2026, while anticipating core earnings per share will rise in the high single-digit range under constant currency conditions.
Keywords: Roche, first quarter sales, Swiss franc, generic competition, CEO Thomas Schinecker, investment in U.S., weight-loss pharmaceuticals, FDA approval, earnings growth.
Original Source: https://www.cnbc.com/2026/04/23/roche-stock-earnings-q1-ceo-swiss-franc-us-investment.html
Category :
Tags:
Publish Date: 2026-04-23 15:16:00
